Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA).
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The completion of this trial marks a key step forward for the company toward regulatory approval. Meanwhile, the company has also announced a series of important upcoming R&D milestones, indicating its continued progress in the field of AL amyloidosis treatment.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like

Circle mintes 250 million new USDC to USDC Treasury
AiCoin•2026/11/22 16:26

Michael Saylor releases Bitcoin Tracker information again, possibly hinting at increased BTC holdings
BlockBeats•2026/11/22 13:21

Crypto prices
MoreBitcoin
BTC
$60,626.01
+0.78%
Ethereum
ETH
$1,712.53
+1.89%
Tether USDt
USDT
$0.9985
+0.08%
BNB
BNB
$556.31
+1.55%
USDC
USDC
$1.0000
+0.01%
XRP
XRP
$0.9268
-0.60%
Solana
SOL
$70.22
-0.50%
TRON
TRX
$0.3049
+0.15%
Hyperliquid
HYPE
$62.43
+2.01%
Zcash
ZEC
$788.97
+0.32%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now
